Johnson & Johnson puts up strong profit and revenue in 4Q

Combined Shape

A big jump in prescription drug sales, particularly overseas, helped Johnson & Johnson swing to a large fourth-quarter profit after posting a huge loss a year ago, when it took a $13.6 billion charge related to the late-2017 U.S. tax overhaul.

The world’s biggest maker of health care products also benefited from an effective tax rate of just 2.6 percent for the latest quarter, along with reduced spending on research and development. It topped Wall Street profit and revenue expectations.

The maker of baby shampoo and biotech drugs on Tuesday reported net income of $3.04 billion, or $1.12 per share, for 2018’s fourth quarter. A year earlier, J&J reported a rare net loss — $10.71 billion, or $3.00 per share. That was due to the $13.6 billion charge, for a tax payment on years of accumulated foreign earnings, amounting to more than $66 billion, brought back to the U.S. at low tax rates.

Earnings in the latest quarter, adjusted for one-time gains and costs, came to $1.97 per share, or 2 cents better than industry analysts expected, according to a survey by Zacks Investment Research.

The New Brunswick, New Jersey- based company said revenue totaled $20.39 billion, also edging out expectations, though that was just 1 percent higher than 2017’s fourth quarter.

Trending:
In Just 4 Months, Biden Manages to Highlight How Competent Trump Was Over Previous 4 Years

As usual, J&J’s prescription drug business drove the strong performance, with sales jumping 5.3 percent to $10.19 billion. Sales of cancer drugs including Darzalex, Imbruviga and Zytiga jumped 22 percent to a total of $2.49 billion, and sales of Remicade, Simponi and Stelara, for rheumatoid arthritis and other immune disorders, rose 8.3 percent to a total of $3.34 billion.

Johnson & Johnson’s consumer health business posted flat sales of $3.54 billion, while the medical devices and diagnostics business, which the company has been revamping for a couple years, saw sales drop 4.4 percent to $6.67 billion.

Johnson & Johnson expects full-year earnings between $8.50 and $8.65 per share, with revenue between $80.4 billion and $81.2 billion. Industry analysts have projected per-share earnings of $8.60 and revenue of about $82.6 billion.

____

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

_____

Portions of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ

The Western Journal has not reviewed this Associated Press story prior to publication. Therefore, it may contain editorial bias or may in some other way not meet our normal editorial standards. It is provided to our readers as a service from The Western Journal.

Truth and Accuracy

Submit a Correction →






We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
Combined Shape
The Associated Press is an independent, not-for-profit news cooperative headquartered in New York City. Their teams in over 100 countries tell the world’s stories, from breaking news to investigative reporting. They provide content and services to help engage audiences worldwide, working with companies of all types, from broadcasters to brands.
The Associated Press was the first private sector organization in the U.S. to operate on a national scale. Over the past 170 years, they have been first to inform the world of many of history's most important moments, from the assassination of Abraham Lincoln and the bombing of Pearl Harbor to the fall of the Shah of Iran and the death of Pope John Paul.

Today, they operate in 263 locations in more than 100 countries relaying breaking news, covering war and conflict and producing enterprise reports that tell the world's stories.
Location
New York City




Conversation